NTES [NetEase,] UPLOAD: (Original Filing)
[]
GRO [AGRIA] SC 13G/A: (Original Filing)
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities]
GRO [AGRIA] SC 13G/A: reporting person’s initial filing on this form with
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 subject to the liabilities]
MR [Mindray Medical International] 6-K: (Original Filing)
[Mindray Announces Second Quarter 2011 Financial Results Shenzhen, China August 8, 2011 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2011. Highlights for Second Quarter 2011 Net revenues were $217.3 million, an increase of 21.2%]
MR [Mindray Medical International] 6-K: Mindray Announces Second Quarter 2011 Financial Results Shenzhen,
[Mindray Announces Second Quarter 2011 Financial Results Shenzhen, China August 8, 2011 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2011. Highlights for Second Quarter 2011 Net revenues were $217.3 million, an increase of 21.2%]
MR [Mindray Medical International] SC 13G: (Original Filing)
[The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed but]
